- Home
- PSNL vs LRMR Comparison
PSNL vs LRMR Comparison
Compare PSNL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- LRMR
- Stock Information
- Founded
- PSNL 2011
- LRMR N/A
- Country
- PSNL United States
- LRMR United States
- Employees
- PSNL N/A
- LRMR N/A
- Industry
- PSNL Medical Specialities
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- LRMR Health Care
- Exchange
- PSNL Nasdaq
- LRMR Nasdaq
- Market Cap
- PSNL 460.7M
- LRMR 426.9M
- IPO Year
- PSNL 2019
- LRMR N/A
- Fundamental
- Price
- PSNL $4.89
- LRMR $3.34
- Analyst Decision
- PSNL Strong Buy
- LRMR Strong Buy
- Analyst Count
- PSNL 4
- LRMR 8
- Target Price
- PSNL $8.56
- LRMR $19.63
- AVG Volume (30 Days)
- PSNL 1.5M
- LRMR 678.8K
- Earning Date
- PSNL 02-26-2025
- LRMR 03-13-2025
- Dividend Yield
- PSNL N/A
- LRMR N/A
- EPS Growth
- PSNL N/A
- LRMR N/A
- EPS
- PSNL N/A
- LRMR N/A
- Revenue
- PSNL $87,489,000.00
- LRMR N/A
- Revenue This Year
- PSNL $15.76
- LRMR N/A
- Revenue Next Year
- PSNL $4.90
- LRMR N/A
- P/E Ratio
- PSNL N/A
- LRMR N/A
- Revenue Growth
- PSNL 24.05
- LRMR N/A
- 52 Week Low
- PSNL $1.12
- LRMR $3.01
- 52 Week High
- PSNL $7.20
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- PSNL 45.39
- LRMR 29.00
- Support Level
- PSNL $5.22
- LRMR $3.24
- Resistance Level
- PSNL $5.50
- LRMR $3.54
- Average True Range (ATR)
- PSNL 0.57
- LRMR 0.22
- MACD
- PSNL -0.18
- LRMR 0.03
- Stochastic Oscillator
- PSNL 8.33
- LRMR 12.26
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.